The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031.
Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Many biologic therapies are currently approved for the treatment of cancer, but due to high cost, it is not affordable in low-income countries. Growing demand for biosimilar and increase in demand for cost-effective treatment in low and medium-income countries drives the growth of the market during the forecast period.
Certain anti-cancer drugs had lost patents along with many drugs are going to lose the patent in coming years; thus, cancer biosimilars are expected to gain popularity in the coming year. A growing number of cancer patients and entry of biosimilars into the market, rising number of mergers and acquisitions by key players to grab the market share further drives the growth of the global cancer biosimilar market. However, complicated manufacturing process and stringent regulatory hurdles for the approval of biosimilars are the factors restrains the growth of the market.
The global cancer biosimilar market is segmented on the basis of Biologic class, Type, Drug Class, Route of Administration, Distribution Channel, and Region. The Bilogic class segment comprises Bevacizumab, Rituximab, Trastuzumab, Filgrastim, Pegfilgrastim, Denosumab, and others (including products approved in developing countries and pipeline products). On the basis of type, the global cancer biosimilar market is segmented into lung cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma, and many more. An increase in the number of cancer patients and approval of biosimilars has boosted the growth of the market. Based on distribution channels, the global biosimilar market is further sub-segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy is a major contributor in terms of revenue to the market due to the increase in the number of hospital visits and hospital stays; however, online pharmacy is witnessed to grow at a higher pace in the forecast period due to an increase in the number of internet users and ease of use. Drug Class Segment consists of G-CSF, Monoclonal Antibody, and Hematopoietic Agents. While Rout of adminstration includes Intravenous, Subcutaneous, and Others.
At the regional level, the global cancer biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America is expected to be the dominant global market over the forecast period. The first biosimilar approved by the U.S. FDA is in 2015, which is almost ten years later than Europe. However, since 2015, the U.S has approved many biosimilar, for instance, as of 2017, FDA approved five biosimilars, out of which two are approved for cancer.
Furthermore, robust clinical pipeline and increasing research and drug development activities propel the growth of the market in North America. Europe is a major contributor to the global cancer biosimilar market. This is partly because of increased government initiatives for cost-effective treatment and an increase in demand for biosimilars. The Asia Pacific is the third promising revenue contributor, which is expected to grow at a rapid pace in the upcoming year. Countries such as Japan, India, and China are major contributors for this market and are identified as most lucrative for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities. Furthermore, low cost biosimilars perfectly suffice to the budgets of the people in this region.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 20.0 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Biologic Class, By Type, By Distribution Channel, By Drug Class, By Route of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Mylan, Amgen, Pfizer, Celltrion, Samsung Bioepis, Bio-Thera Solutions, Sandoz (Novartis), Teva, Coherus BioSciences, CuraTeQ Biologics, Accord Healthcare, Allergan, Biocon, Merck, Accord BioPharma, Accord Healthcare S.L.U., AffaMed, Biosimilar Collaborations Ireland Limited, Dr. Reddy’s, Henlius, Intas, Mabxience, Nippon Kayaku, Sandoz GmbH, Amgen Inc., Amneal Pharmaceuticals, Inc., Betta Pharmaceuticals/Beijing Mabworks, Bio-Thera Solutions, Ltd., Celltrion, Inc., Cipla, Dr. Reddy’s Laboratories, FGK Representative Service GmbH, Hetero, Innovent Biologics, mAbxience Holding, S.L., Outlook Therapeutics Limited, Pfizer Inc., Roche Registration GmbH, Samsung Bioepis NL B.V., Sandoz Inc., Shanghai Henlius Biotech, STADA Arzneimittel AG, TOT BIOPHARM, AstraZeneca PLC, Samsung Bioepis Co., Ltd., Organon & Co., and other prominent players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biosimilars Market Snapshot
Chapter 4. Global Cancer Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Biologic Class Estimates & Trend Analysis
5.1. By Biologic Class & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Biologic Class:
5.2.1. Bevacizumab
5.2.2. Rituximab
5.2.3. Trastuzumab
5.2.4. Filgrastim
5.2.5. Pegfilgrastim
5.2.6. Denosumab
5.2.7. Others (Products approved in developing countries & pipeline products)
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Type:
6.2.1. Lung Cancer
6.2.2. Breast cancer
6.2.3. Ovarian cancer
6.2.4. Prostate cancer
6.2.5. Lymphoma
6.2.6. Others
Chapter 7. Market Segmentation 3: By Drug Class Estimates & Trend Analysis
7.1. By Drug Class & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Drug Class:
7.2.1. G-CSF
7.2.2. Monoclonal Antibody
Chapter 8. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis
8.1. By Route of Administration & Market Share, 2021 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Route of Administration:
8.2.1. Intravenous
8.2.2. Subcutaneous
8.2.3. Others
Chapter 9. Market Segmentation 5: By Distribution Channel Estimates & Trend Analysis
9.1. By Distribution Channel & Market Share, 2021 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Distribution Channel:
9.2.1. Hospital Pharmacy
9.2.2. Retail Pharmacy
9.2.3. Online Pharmacy
9.2.4. Others
Chapter 10. Cancer Biosimilars Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.1.2. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.1.3. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.1.4. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.1.5. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.1.6. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2025 - 2034
10.2. Europe
10.2.1. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.2.2. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.2.3. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.2.4. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.2.5. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.2.6. Europe Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.3.2. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.3.3. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.3.4. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.3.5. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.3.6. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.4. Latin America
10.4.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.4.2. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.4.3. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.4.4. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.4.5. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.4.6. Latin America Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.5.2. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.5.3. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.5.4. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.5.5. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.5.6. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Mylan
11.2.2. Amgen
11.2.3. Pfizer
11.2.4. Celltrion
11.2.5. Samsung Bioepis
11.2.6. Bio-Thera Solutions
11.2.7. Sandoz (Novartis)
11.2.8. Teva
11.2.9. Coherus BioSciences
11.2.10. CuraTeQ Biologics
11.2.11. Accord Healthcare
11.2.12. Allergan
11.2.13. Biocon
11.2.14. Merck
11.2.15. Accord BioPharma
11.2.16. Accord Healthcare S.L.U.
11.2.17. AffaMed
11.2.18. Biosimilar Collaborations Ireland Limited
11.2.19. Dr. Reddy’s
11.2.20. Henlius
11.2.21. Intas
11.2.22. Mabxience
11.2.23. Nippon Kayaku
11.2.24. Sandoz GmbH
11.2.25. Amgen Inc.
11.2.26. Amneal Pharmaceuticals, Inc.
11.2.27. Betta Pharmaceuticals/Beijing Mabworks
11.2.28. Bio-Thera Solutions, Ltd.
11.2.29. Celltrion, Inc.
11.2.30. Cipla
11.2.31. Dr. Reddy’s Laboratories
11.2.32. FGK Representative Service GmbH
11.2.33. Hetero
11.2.34. Innovent Biologics
11.2.35. mAbxience Holding, S.L.
11.2.36. Outlook Therapeutics Limited
11.2.37. Pfizer Inc.
11.2.38. Roche Registration GmbH
11.2.39. Samsung Bioepis NL B.V.
11.2.40. Sandoz Inc.
11.2.41. Shanghai Henlius Biotech
11.2.42. STADA Arzneimittel AG
11.2.43. TOT BIOPHARM
11.2.44. AstraZeneca PLC
11.2.45. Samsung Bioepis Co., Ltd.
11.2.46. Organon & Co.
11.2.47. Other Prominent Player
Global Cancer Biosimilars Market Outlook By Biologic class
Global Cancer Biosimilars Market Outlook By Type
Global Cancer Biosimilars Market Outlook By Drug Class
Global Cancer Biosimilars Market Outlook By Route Of Administration
Global Cancer Biosimilars Market Outlook By Distribution channel
Global Cancer Biosimilar Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
